The price of innovation: new estimates of drug development costs
The price of innovation: new estimates of drug development costs
复制标题
DOI：
10.1016/s0167-6296(02)00126-1
复制
发表时间：
2003-03-01
影响因子：
3.5
通讯作者：
Grabowski, HG
中科院分区：
文献类型：
--
作者：
DiMasi, JA;Hansen, RW;Grabowski, HG
通过对10家制药企业的调查，随机抽取68种新药的研发成本。这些数据被用来估计新药开发的平均税前成本。在测试过程中放弃的化合物的成本与获得市场批准的化合物的成本有关。估计每个新药的平均自付费用为4.03亿美元（2000美元）。按11%的实际折扣率将自付费用资本化到市场批准点，则批准前的总成本估计为8.02亿美元（2000美元）。与早期采用类似方法的研究结果相比，总资本化成本的年增长率比一般价格通胀率高7.4%。(C) 2003 Elsevier Science B.V.版权所有
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval. The estimated average out-of-pocket cost per new drug is US$ 403 million (2000 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 11 % yields a total pre-approval cost estimate of US$ 802 million (2000 dollars). When compared to the results of an earlier study with a similar methodology, total capitalized costs were shown to have increased at an annual rate of 7.4% above general price inflation. (C) 2003 Elsevier Science B.V. All rights reserved.